Groups

  Plasma

Brain

Liver

Kidney

GSH

GSSG

GSH

GSSG

GSH

GSSG

GSH

GSSG

Control group

3.96  ±  0.96

0.81  ± 0.17

4.89  ±  0.88

0.55 ±  0.11

5.78  ±  0.55

0.64 ±   0.06

2.60  ±  0.04

0.54  ± 0.13

Cadmium exposed group

1.55 ± 0.48***

1.03  ± 0.64ns

2.25  ±  1.01***

0.89 ± 0.091***

2.69 ±  0.33***

0.91 ±  0.05***

1.87 ±  0.08***

0.71 ±  0.15*

Ceftriaxone plus sulbactam with VRP1034 treated group

2.09 ±  0.85ns

0.78   ± 11ns

3.96  ±  0.66***

0.64 ±  0.10***

4.00 ±  0.62***

0.77  ±  0.08***

2.39  ± 0.17***

0.60 ±  0.09ns

All data are Mean ± SD of each group. The GSH and GSSG levels were expressed in the plasma (mg/dL) whereas in the tissues (μmole/gm tissue). Newman keuls test was performed for statistical significance between control group vs Cd exposed group and Cd exposed group vs ceftriaxone plus sulbactam with VRP1034 treated group. Where ***p<0.001 (highly significant) **p<0.01(significant); p<0.05 (significant) Nsp>0.05 (non significant).
Table 1: Effect of ceftriaxone plus sulbactam with VRP1034 on GSH, GSSG levels in cadmium exposed group after 21 days treatment.